Condition: Ulcerative Colitis · Sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd.
The primary purpose of this study is to evaluate the safety and tolerability of H021 tablets following oral administration of single and multiple ascending doses in healthy participants.
This description comes directly from the study's public registry record.
Dr. Ofer Gonen · 0385939801 · o.gonen@nucleusnetwork.com.au
Always discuss trial participation with your own doctor first.
| Nucleus Network Ply Ltd. | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06627556